A fourth DEA extension keeps telehealth prescribing of buprenorphine and other controlled medications alive through December 2026, but permanent rules remain pending.
Key Takeaways
- The telehealth flexibilities live, for now: A fourth temporary DEA extension keeps telehealth prescribing of controlled medications, including buprenorphine for opioid use disorder, in effect through December 31, 2026. Without it, providers would have faced a return to pre-2020 in-person requirements.
- The reprieve is temporary and repetitive: This is the fourth short-term extension since 2023, and the permanent framework, including a promised special registration for telemedicine prescribers, remains unfinished. The cycle of last-minute extensions has become the status quo.
- Two narrower final rules are now in force: A buprenorphine-specific rule and a Veterans Affairs continuity rule took effect at the end of 2025, layering authorities operators must track. The buprenorphine rule allows six months of virtual prescribing to a new patient.
- Operators should plan for volatility: Telehealth is now central to addiction-treatment access, but the regulatory foundation resets annually. Providers should build workflows that adapt if a permanent rule imposes new requirements, and watch the special-registration proposal.
It has become a strange annual ritual in American addiction medicine. As the calendar tips toward year’s end, providers who treat opioid use disorder over video calls watch a regulatory clock run down, unsure until nearly the last minute whether the rules that let them do their jobs will survive into January. At the end of December 2025 the ritual played out again. With pandemic-era telehealth flexibilities set to expire and no permanent replacement in view, the Drug Enforcement Administration, working with the Department of Health and Human Services, granted an extension hours before the deadline, carrying the rules through December 31, 2026.
The flexibility in question is not a small one. It governs whether a clinician can start a patient on buprenorphine, the workhorse medication for opioid dependence, without ever meeting that patient in person. For most of the past century the answer was no, a stance rooted in the Ryan Haight Act of 2008, which generally required an in-person visit before a controlled substance could be prescribed. The COVID-19 emergency swept that requirement aside, and remote prescribing of buprenorphine turned out to be a lifeline, especially in rural counties and for the many patients who cannot easily reach a clinic. It was always meant to be temporary, and the treatment field has since lived through a recurring cycle of near-expirations and last-minute extensions. What nobody seems able to do is make it permanent.
What the Fourth DEA Telehealth Extension Does
The Fourth Temporary Extension, announced in the final days of December 2025 and effective January 1, 2026, freezes the arrangement that has held since 2020. Under it a DEA-registered clinician can prescribe Schedule II through V medications over an audio-video visit with no prior in-person exam, and can prescribe the Schedule III through V narcotics approved for opioid use disorder, buprenorphine chief among them, over an audio-only call, again with no in-person visit. The extension adds nothing new. It simply forestalls what the field has taken to calling the “telemedicine cliff,” the sudden snapback to pre-pandemic rules that would sever remote prescribing until some permanent regime exists.
The agencies made no pretense that this is a destination. They called it what it is, a bridge, bought to give them time to finish permanent regulations, including a long-promised special registration that would create a formal lane for telemedicine prescribers and train extra scrutiny on the online platforms. That proposal surfaced in the last days of the previous administration, in January 2025, and has sat unfinished since, its fate under the current administration unclear.
Three Overlapping Telehealth Prescribing Authorities
What began as a single emergency waiver has quietly become a stack, and operators need to know which layer they are standing on. Alongside the broad temporary extension, two narrower final rules took effect at the end of 2025, after being delayed twice. The first, with the ungainly title Expansion of Buprenorphine Treatment via Telemedicine Encounter, lets a clinician prescribe up to six months of buprenorphine to a new patient never seen in person, a real but bounded authority that still leans on the eventual special registration to become permanent. The second extends continuity-of-care flexibility to Veterans Affairs patients. Because the temporary extension asks less of a prescriber than either final rule, a clinician covered by one of those rules may still elect to work under the broader temporary authority. Three sets of conditions, running at the same time, each with its own fine print.
Why Annual DEA Extensions Undermine Addiction Treatment
The extensions have kept the medicine flowing, but the pattern itself has become the problem. This is the fourth temporary reprieve since the DEA and SAMHSA first floated permanent telemedicine rules back in early 2023, a proposal that drew a record pile of public comments and then went nowhere. Each extension has arrived at the edge of its deadline; the latest cleared it by hours. Clinics book patients weeks ahead, and the uncertainty forces treatment organizations to plan their operations around a rule that could, in principle, be rewritten every twelve months, a short-term-extension pattern that leaves providers unable to invest in durable infrastructure. The danger is not hypothetical. When Medicare’s separate telehealth flexibilities briefly lapsed during a government shutdown in the fall of 2025, one analysis of medical records caught a sharp drop in telemedicine visits within weeks, a small preview of what a true cliff would do to a population for whom a missed prescription can mean relapse.
For a treatment model that increasingly runs on telehealth, that volatility quietly taxes everything. It is hard to build durable programs, recruit prescribers, or raise capital against an authority that resets each New Year’s Eve, and the wobble compounds the reimbursement uncertainty that already dogs medication-assisted treatment. The wider behavioral health field has watched Medicare make its telehealth flexibilities for mental-health services permanent, which only sharpens the contrast: the controlled-substance rules that matter most to addiction care remain the least settled of all, even as the integrated models that pair medication with counseling depend on them holding.
How SUD Providers Should Handle Telehealth Uncertainty
The practical advice follows from the uncertainty rather than fighting it. Treat the current flexibilities as solid through the end of 2026 and no further. Build telehealth workflows that can bend if a permanent rule lands with new obligations attached. Document which authority each prescription rests on. Read the special-registration proposal closely for hints about identity checks, prescription-monitoring requirements, data reporting, and platform-level rules a final version might carry. And keep the ability to bring a patient in for an in-person visit if the rules tighten. State law matters here too, since the federal extension does not override it and increasingly dictates what telehealth prescribing looks like on the ground, a pattern visible in the uneven, state-by-state economics of addiction treatment. All of it is unfolding while Medicaid, the largest payer of addiction care, absorbs roughly a trillion dollars in federal cuts.
The larger truth is that remote prescribing of buprenorphine has quietly become load-bearing infrastructure for opioid treatment in this country, and its legal foundation is renewed one year at a time, always at the last minute. The fourth extension is genuinely good news for access in 2026. The open question is whether 2027 brings a permanent framework or a fifth trip to the edge of the same cliff. Until the DEA finally finishes a lasting rule, the safest thing an operator can assume is that the ground will move again, and the ones who plan for the tremor will be the ones still standing when it comes.
